Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...
A phase 2/3 study of romiplostim N01 in chemotherapy-induced thrombocytopenia (CIT). Baseline characteristics of parents enrolled in ACCL20N1CD: Financial distress during treatment for pediatric acute ...
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 The study cohort consisted ...
The March 20, 2024, article by Berman et al entitled “CML and the WHO: Why?” (J Clin Oncol 10.1200/JCO.23.01689) was published with an error. In the author list ...
Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan We studied a ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Evolution of overall survival (OS) after curative-intent lung cancer surgery in a population-based Mississippi Delta cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium.
Optimizing clinical research in a regional cancer center network: A multidepartment survey-based approach. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback